Related Experiment Video
Updated: Nov 17, 2025
Retzius-Sparing Robot-Assisted Radical Prostatectomy
Published on: May 19, 2022
Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review
Gaëtan Devos1, Bram Vansevenant2, Gert De Meerleer3
1Department of Urology, University Hospitals Leuven, Leuven, Belgium. gaetan.devos@uzleuven.be.
Context:
There is an urgent need to develop novel treatment strategies in patients with unfavorable intermediate- and high-risk localized prostate cancer (PCa) to optimize the outcome of these patients. Androgen receptor signaling inhibitors (ARSI) have demonstrated a survival benefit in metastatic hormonesensitive and castration-resistant PCa. A similar benefit might be expected in the localized setting.
Objective:
To perform a systematic review about the role of neoadjuvant ARSI in unfavorable intermediate and high-risk localized PCa.
Evidence Acquisition:
We performed a systematic review of the following databases: MEDLINE (PubMed), EMBASE, Cochrane Library and Web of Science. Publications of ASCO were consulted to identify meeting abstract with early results of ongoing trials. This systematic review was performed and reported in accordance with the PRISMA guidelines.
Evidence Synthesis:
Pathological complete response (pCR) following neoadjuvant ARSI treatment was observed in 4%-13% of the patients. Minimal residual disease response ranged from 36% to 73.9% when defined as residual cancer burden < 0.25 cm3 at final pathology and from 8% to 20% when defined as the diameter of the remaining tumor < 5 mm. Despite intense neoadjuvant ARSI treatment, residual pT3 disease was observed in 48%-76% of the patients. In contrast, positive surgical margins (PSM) were present in only 5%-22%. Only one trial reported BCR following neoadjuvant ARSI therapy (44% BCR at a median follow-up of 4 years).
Conclusion:
Despite intense neoadjuvant ARSI therapy, pCR is rarely attained and high proportions of pT3 disease are still observed at final pathology. In contrast, promising results are obtained in terms of PSMs. Long-term survival outcomes are eagerly awaited.
Insights
Neoadjuvant Androgen Receptor Signaling Inhibitors (ARSI) show limited pathological complete response but reduce positive surgical margins in localized prostate cancer. Long-term survival data are needed to confirm benefits for high-risk patients.
Area of Science:
- Oncology
- Urology
- Medical Research
Background:
- High-risk localized prostate cancer (PCa) requires novel treatments.
- Androgen Receptor Signaling Inhibitors (ARSI) improve outcomes in metastatic PCa.
- ARSI may benefit localized PCa when used neoadjuvantly.
Purpose of the Study:
- Systematically review neoadjuvant ARSI use in unfavorable intermediate and high-risk localized PCa.
- Evaluate treatment efficacy and pathological outcomes.
Main Methods:
- Systematic review of MEDLINE, EMBASE, Cochrane Library, and Web of Science.
- Inclusion of ASCO meeting abstracts for early trial results.
- Reporting adherence to PRISMA guidelines.
Main Results:
- Pathological complete response (pCR) rates ranged from 4%-13%.
- Minimal residual disease rates varied (36%-73.9% or 8%-20%).
- Residual pT3 disease observed in 48%-76%, while positive surgical margins (PSM) were 5%-22%.
Conclusions:
- Neoadjuvant ARSI therapy rarely achieves pCR and often leaves residual pT3 disease.
- Promising reductions in positive surgical margins (PSM) were noted.
- Long-term survival outcomes require further investigation.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
09:49Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy
Published on: December 28, 2021